Timothy Spears, DO
Family Medicine · Iola, KSNPI 1639173156
Payments from drug & device makers
Across 324 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$901
- AbbVie$876
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$595
- Lilly USA, LLC$303
- Takeda Pharmaceuticals U.S.A., Inc.$276
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$221
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,82599%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $901 |
| AbbVie(2 entities) | 85 | $876 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $595 |
| Lilly USA, LLC | 21 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $276 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $221 |
| AstraZeneca | 14 | $214 |
| Pfizer | 18 | $154 |
| GSK | 8 | $132 |
| Eisai Inc. | 6 | $116 |
| Boehringer Ingelheim | 7 | $104 |
| Merck | 6 | $87 |
| Supernus Pharmaceuticals, Inc. | 5 | $72 |
| Vanda Pharmaceuticals Inc. | 4 | $71 |
| Otsuka America Pharmaceutical, Inc. | 4 | $70 |
| Nestle Healthcare Nutrition Inc. | 3 | $69 |
| Amgen | 3 | $51 |
| Mylan Specialty L.p. | 3 | $47 |
| Amarin Pharma, Inc. | 3 | $47 |
| Lundbeck LLC | 2 | $43 |
| Bayer | 3 | $41 |
| Vertex | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Sanofi Pasteur Inc. | 1 | $27 |
| Genentech USA, Inc. | 2 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Corium, LLC | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Organogenesis Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Grifols USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,851 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 12 | $56,823 |
| RexultiBrexpiprazole | 34 | $53,742 |
| OzempicSemaglutide | 54 | $52,291 |
| VraylarCariprazine Hcl | 40 | $43,267 |
| OxycontinOxycodone Hcl | 28 | $33,936 |
| MyrbetriqMirabegron | 59 | $30,304 |
| EliquisApixaban | 52 | $29,514 |
| MounjaroTirzepatide | 24 | $25,600 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $22,856 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $21,764 |
| JanuviaSitagliptin Phosphate | 37 | $21,329 |
| TrulicityDulaglutide | 25 | $19,803 |
| FarxigaDapagliflozin Propanediol | 28 | $19,540 |
| LinzessLinaclotide | 20 | $18,634 |
| TrintellixVortioxetine Hydrobromide | 28 | $12,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess | $876 | $61,90160 claims |
| Acadia Pharmaceuticals IncNuplazid | $17 | $56,82312 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $70 | $53,74234 claims |
| Novo NordiskOzempic | $901 | $52,29154 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $214 | $49,57898 claims |
| Lilly USA, LLCMounjaro, Trulicity | $303 | $45,40249 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $132 | $30,64955 claims |
| PfizerEliquis | $154 | $29,51452 claims |
| MerckJanuvia | $87 | $21,32937 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $276 | $12,90828 claims |
| Boehringer IngelheimSpiriva Respimat | $104 | $11,24321 claims |
| Johnson & JohnsonXarelto | $22 | $9,52922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Iola
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.